 Jose Castillo-Mancilla
Concepts (273)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-HIV Agents | 51 | 2025 | 888 | 10.650 |
Why?
| | HIV Infections | 76 | 2025 | 3154 | 8.660 |
Why?
| | Adenine | 28 | 2024 | 339 | 5.490 |
Why?
| | Organophosphates | 24 | 2025 | 187 | 5.200 |
Why?
| | Tenofovir | 26 | 2024 | 295 | 4.050 |
Why?
| | Emtricitabine | 22 | 2024 | 205 | 3.900 |
Why?
| | Medication Adherence | 28 | 2024 | 539 | 3.870 |
Why?
| | Dried Blood Spot Testing | 13 | 2024 | 126 | 3.590 |
Why?
| | Viral Load | 17 | 2025 | 526 | 3.190 |
Why?
| | Drug Monitoring | 9 | 2024 | 395 | 2.870 |
Why?
| | Pre-Exposure Prophylaxis | 13 | 2022 | 246 | 2.000 |
Why?
| | HIV-1 | 11 | 2025 | 896 | 1.970 |
Why?
| | Viremia | 8 | 2024 | 158 | 1.920 |
Why?
| | Anti-Retroviral Agents | 8 | 2023 | 250 | 1.800 |
Why?
| | Sustained Virologic Response | 4 | 2025 | 46 | 1.500 |
Why?
| | Blood Chemical Analysis | 7 | 2019 | 109 | 1.040 |
Why?
| | Organophosphonates | 3 | 2015 | 97 | 0.880 |
Why?
| | HIV | 6 | 2022 | 250 | 0.870 |
Why?
| | Adult | 53 | 2025 | 40449 | 0.860 |
Why?
| | Deoxycytidine | 3 | 2015 | 221 | 0.830 |
Why?
| | Desiccation | 2 | 2014 | 24 | 0.810 |
Why?
| | Diabetes Mellitus | 2 | 2024 | 1098 | 0.810 |
Why?
| | Drug Resistance, Viral | 3 | 2025 | 122 | 0.790 |
Why?
| | Humans | 91 | 2025 | 144759 | 0.740 |
Why?
| | Awards and Prizes | 1 | 2023 | 70 | 0.730 |
Why?
| | Prospective Studies | 18 | 2023 | 7990 | 0.720 |
Why?
| | Specimen Handling | 2 | 2014 | 186 | 0.710 |
Why?
| | Inflammation | 6 | 2021 | 2878 | 0.680 |
Why?
| | South Africa | 9 | 2023 | 261 | 0.680 |
Why?
| | Antiretroviral Therapy, Highly Active | 2 | 2020 | 278 | 0.670 |
Why?
| | Female | 56 | 2025 | 78271 | 0.660 |
Why?
| | Antiviral Agents | 4 | 2019 | 767 | 0.660 |
Why?
| | Male | 52 | 2025 | 72315 | 0.640 |
Why?
| | Middle Aged | 31 | 2025 | 35875 | 0.590 |
Why?
| | Biomarkers | 10 | 2022 | 4271 | 0.580 |
Why?
| | Biomedical Research | 2 | 2023 | 710 | 0.550 |
Why?
| | Atazanavir Sulfate | 2 | 2016 | 42 | 0.490 |
Why?
| | Pharmacogenetics | 2 | 2016 | 172 | 0.450 |
Why?
| | Lymphocyte Activation | 2 | 2018 | 1126 | 0.440 |
Why?
| | Pyridones | 4 | 2025 | 199 | 0.440 |
Why?
| | Mental Health Services | 1 | 2019 | 473 | 0.410 |
Why?
| | Polyphosphates | 5 | 2022 | 45 | 0.410 |
Why?
| | CD4 Lymphocyte Count | 3 | 2025 | 277 | 0.400 |
Why?
| | Sexual and Gender Minorities | 4 | 2022 | 251 | 0.400 |
Why?
| | Interleukin-6 | 5 | 2021 | 780 | 0.400 |
Why?
| | Tandem Mass Spectrometry | 7 | 2022 | 576 | 0.390 |
Why?
| | Chromatography, Liquid | 6 | 2019 | 454 | 0.390 |
Why?
| | Transgender Persons | 1 | 2016 | 191 | 0.390 |
Why?
| | HIV Seropositivity | 2 | 2023 | 119 | 0.380 |
Why?
| | Immunologic Factors | 1 | 2015 | 255 | 0.380 |
Why?
| | Lipopolysaccharide Receptors | 4 | 2021 | 87 | 0.370 |
Why?
| | Sofosbuvir | 4 | 2022 | 61 | 0.370 |
Why?
| | Emigrants and Immigrants | 2 | 2012 | 157 | 0.360 |
Why?
| | Self Report | 4 | 2023 | 872 | 0.360 |
Why?
| | Unsafe Sex | 1 | 2012 | 61 | 0.350 |
Why?
| | Fibrin Fibrinogen Degradation Products | 4 | 2019 | 93 | 0.350 |
Why?
| | Minority Groups | 1 | 2014 | 282 | 0.350 |
Why?
| | HIV Integrase Inhibitors | 2 | 2025 | 78 | 0.340 |
Why?
| | Hair | 4 | 2020 | 88 | 0.340 |
Why?
| | Cupriavidus | 1 | 2010 | 3 | 0.320 |
Why?
| | Mental Disorders | 1 | 2019 | 1168 | 0.320 |
Why?
| | Alanine | 4 | 2024 | 171 | 0.320 |
Why?
| | Aging | 2 | 2021 | 1966 | 0.310 |
Why?
| | Acquired Immunodeficiency Syndrome | 3 | 2019 | 235 | 0.310 |
Why?
| | Gram-Negative Bacterial Infections | 1 | 2010 | 51 | 0.310 |
Why?
| | Communicable Disease Control | 1 | 2010 | 86 | 0.300 |
Why?
| | Clinical Trials as Topic | 2 | 2015 | 1053 | 0.300 |
Why?
| | Phosphorous Acids | 2 | 2019 | 15 | 0.300 |
Why?
| | Prosthesis-Related Infections | 1 | 2010 | 99 | 0.290 |
Why?
| | Leukocytes, Mononuclear | 6 | 2021 | 573 | 0.290 |
Why?
| | Hepatitis C | 3 | 2022 | 254 | 0.290 |
Why?
| | Homosexuality, Male | 4 | 2022 | 222 | 0.280 |
Why?
| | Health Services Accessibility | 2 | 2015 | 1098 | 0.280 |
Why?
| | Young Adult | 16 | 2025 | 14105 | 0.260 |
Why?
| | Frailty | 2 | 2022 | 198 | 0.260 |
Why?
| | Peripartum Period | 2 | 2024 | 19 | 0.260 |
Why?
| | Uganda | 4 | 2021 | 93 | 0.250 |
Why?
| | Deoxyadenine Nucleotides | 2 | 2016 | 15 | 0.250 |
Why?
| | Deoxycytosine Nucleotides | 2 | 2016 | 13 | 0.250 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2022 | 439 | 0.240 |
Why?
| | Defibrillators, Implantable | 1 | 2010 | 382 | 0.240 |
Why?
| | Benchmarking | 2 | 2024 | 188 | 0.230 |
Why?
| | Comorbidity | 3 | 2020 | 1658 | 0.230 |
Why?
| | Diketopiperazines | 2 | 2022 | 22 | 0.230 |
Why?
| | Cryoglobulinemia | 1 | 2005 | 5 | 0.230 |
Why?
| | Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2005 | 8 | 0.230 |
Why?
| | Blood Transfusion | 1 | 2008 | 405 | 0.220 |
Why?
| | Fluorenes | 3 | 2020 | 46 | 0.220 |
Why?
| | Plasma | 2 | 2020 | 225 | 0.220 |
Why?
| | Piperazines | 2 | 2025 | 381 | 0.220 |
Why?
| | Lymphoproliferative Disorders | 1 | 2005 | 57 | 0.220 |
Why?
| | Case-Control Studies | 4 | 2022 | 3604 | 0.220 |
Why?
| | Half-Life | 2 | 2016 | 151 | 0.210 |
Why?
| | RNA, Viral | 2 | 2025 | 688 | 0.210 |
Why?
| | Drug Interactions | 3 | 2020 | 398 | 0.210 |
Why?
| | Benzimidazoles | 3 | 2020 | 190 | 0.200 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2004 | 111 | 0.200 |
Why?
| | HIV Protease Inhibitors | 2 | 2016 | 69 | 0.200 |
Why?
| | Cross Infection | 2 | 2013 | 262 | 0.200 |
Why?
| | Predictive Value of Tests | 2 | 2019 | 2115 | 0.200 |
Why?
| | Medical Waste | 1 | 2003 | 2 | 0.200 |
Why?
| | Medical Waste Disposal | 1 | 2003 | 3 | 0.200 |
Why?
| | Waste Management | 1 | 2003 | 11 | 0.190 |
Why?
| | Financing, Organized | 1 | 2023 | 36 | 0.190 |
Why?
| | Disposable Equipment | 1 | 2003 | 24 | 0.190 |
Why?
| | Telemedicine | 2 | 2022 | 945 | 0.190 |
Why?
| | Body Fluids | 1 | 2003 | 70 | 0.190 |
Why?
| | Syringes | 1 | 2003 | 49 | 0.190 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2023 | 140 | 0.190 |
Why?
| | Tablets | 1 | 2022 | 41 | 0.180 |
Why?
| | Shock, Septic | 1 | 2004 | 216 | 0.180 |
Why?
| | Sexual Behavior | 2 | 2019 | 491 | 0.180 |
Why?
| | Registries | 2 | 2013 | 2385 | 0.180 |
Why?
| | Faculty | 1 | 2023 | 149 | 0.180 |
Why?
| | Adolescent | 11 | 2023 | 22428 | 0.180 |
Why?
| | Cell Phone | 1 | 2022 | 82 | 0.180 |
Why?
| | Demography | 1 | 2022 | 288 | 0.180 |
Why?
| | Africa | 1 | 2021 | 116 | 0.170 |
Why?
| | Protease Inhibitors | 2 | 2020 | 102 | 0.170 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2004 | 392 | 0.170 |
Why?
| | Mentors | 1 | 2023 | 219 | 0.170 |
Why?
| | Meningitis, Cryptococcal | 1 | 2021 | 34 | 0.160 |
Why?
| | Longitudinal Studies | 5 | 2023 | 2947 | 0.160 |
Why?
| | Postpartum Period | 4 | 2024 | 365 | 0.150 |
Why?
| | Mobile Applications | 1 | 2022 | 196 | 0.150 |
Why?
| | Monitoring, Ambulatory | 1 | 2020 | 88 | 0.150 |
Why?
| | Cohort Studies | 4 | 2024 | 5960 | 0.150 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2019 | 138 | 0.140 |
Why?
| | Intensive Care Units | 1 | 2005 | 916 | 0.140 |
Why?
| | Lung Diseases, Interstitial | 1 | 2005 | 660 | 0.140 |
Why?
| | Disease Transmission, Infectious | 2 | 2018 | 69 | 0.140 |
Why?
| | Erythrocytes | 2 | 2016 | 757 | 0.140 |
Why?
| | Simeprevir | 1 | 2018 | 5 | 0.140 |
Why?
| | Treatment Outcome | 3 | 2025 | 11679 | 0.140 |
Why?
| | Rectum | 2 | 2016 | 180 | 0.140 |
Why?
| | Directly Observed Therapy | 1 | 2017 | 15 | 0.130 |
Why?
| | Heterocyclic Compounds, 3-Ring | 1 | 2018 | 44 | 0.130 |
Why?
| | Incidence | 1 | 2024 | 2879 | 0.130 |
Why?
| | United States | 5 | 2023 | 15966 | 0.130 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2017 | 114 | 0.130 |
Why?
| | Drug Therapy, Combination | 2 | 2018 | 1047 | 0.130 |
Why?
| | Clinical Studies as Topic | 1 | 2016 | 12 | 0.130 |
Why?
| | Deoxyguanine Nucleotides | 1 | 2016 | 12 | 0.120 |
Why?
| | Thymine Nucleotides | 1 | 2016 | 19 | 0.120 |
Why?
| | Mental Health | 2 | 2022 | 790 | 0.120 |
Why?
| | Genitalia | 1 | 2016 | 34 | 0.120 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2017 | 221 | 0.120 |
Why?
| | Qualitative Research | 1 | 2024 | 1671 | 0.120 |
Why?
| | Directive Counseling | 1 | 2016 | 44 | 0.120 |
Why?
| | Radio Frequency Identification Device | 1 | 2015 | 2 | 0.120 |
Why?
| | Peru | 1 | 2016 | 62 | 0.120 |
Why?
| | Aged | 6 | 2020 | 25913 | 0.120 |
Why?
| | Biological Assay | 1 | 2016 | 128 | 0.110 |
Why?
| | Program Evaluation | 1 | 2019 | 948 | 0.110 |
Why?
| | Drug Administration Schedule | 1 | 2016 | 779 | 0.110 |
Why?
| | Biosensing Techniques | 1 | 2015 | 139 | 0.100 |
Why?
| | Polymorphism, Genetic | 1 | 2016 | 612 | 0.100 |
Why?
| | Health Status Disparities | 1 | 2016 | 321 | 0.100 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2016 | 299 | 0.100 |
Why?
| | Kenya | 2 | 2024 | 129 | 0.090 |
Why?
| | Enterobacteriaceae Infections | 1 | 2013 | 41 | 0.090 |
Why?
| | Cross-Over Studies | 3 | 2020 | 601 | 0.090 |
Why?
| | Infection Control | 2 | 2005 | 172 | 0.090 |
Why?
| | Quality of Life | 2 | 2022 | 3185 | 0.090 |
Why?
| | Curriculum | 1 | 2019 | 1059 | 0.090 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2018 | 917 | 0.090 |
Why?
| | Ritonavir | 1 | 2012 | 75 | 0.090 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2012 | 93 | 0.090 |
Why?
| | Cardiovascular Diseases | 1 | 2022 | 2168 | 0.080 |
Why?
| | Bacteremia | 1 | 2013 | 221 | 0.080 |
Why?
| | Oligopeptides | 1 | 2012 | 269 | 0.080 |
Why?
| | Time Factors | 5 | 2019 | 7173 | 0.080 |
Why?
| | Aged, 80 and over | 2 | 2020 | 8265 | 0.080 |
Why?
| | Residence Characteristics | 1 | 2013 | 377 | 0.080 |
Why?
| | Pregnancy | 4 | 2024 | 7190 | 0.080 |
Why?
| | Diphosphates | 2 | 2021 | 20 | 0.080 |
Why?
| | Cognition | 1 | 2017 | 1266 | 0.070 |
Why?
| | Microbial Sensitivity Tests | 1 | 2010 | 370 | 0.070 |
Why?
| | Blood Banks | 1 | 2008 | 50 | 0.070 |
Why?
| | Logistic Models | 1 | 2014 | 2117 | 0.070 |
Why?
| | Hepacivirus | 2 | 2022 | 243 | 0.070 |
Why?
| | Transfusion Reaction | 1 | 2008 | 63 | 0.070 |
Why?
| | Internship and Residency | 1 | 2019 | 1257 | 0.070 |
Why?
| | Mexico | 1 | 2008 | 233 | 0.070 |
Why?
| | Feasibility Studies | 2 | 2023 | 1095 | 0.070 |
Why?
| | Surveys and Questionnaires | 3 | 2015 | 6048 | 0.070 |
Why?
| | Pyridines | 1 | 2012 | 605 | 0.070 |
Why?
| | Cross-Sectional Studies | 1 | 2019 | 5868 | 0.070 |
Why?
| | Polymerase Chain Reaction | 1 | 2010 | 1054 | 0.060 |
Why?
| | Pilot Projects | 2 | 2023 | 1886 | 0.060 |
Why?
| | Itraconazole | 1 | 2006 | 7 | 0.060 |
Why?
| | Blastomycosis | 1 | 2006 | 11 | 0.060 |
Why?
| | Molecular Sequence Data | 1 | 2010 | 2930 | 0.060 |
Why?
| | Disease Outbreaks | 1 | 2008 | 422 | 0.060 |
Why?
| | Age Factors | 3 | 2019 | 3333 | 0.060 |
Why?
| | Antifungal Agents | 1 | 2006 | 149 | 0.060 |
Why?
| | Cough | 1 | 2006 | 124 | 0.050 |
Why?
| | HIV Integrase | 1 | 2025 | 74 | 0.050 |
Why?
| | Hematocrit | 2 | 2016 | 108 | 0.050 |
Why?
| | Face | 1 | 2006 | 173 | 0.050 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2012 | 2145 | 0.050 |
Why?
| | Retrospective Studies | 3 | 2022 | 17066 | 0.050 |
Why?
| | Proviruses | 1 | 2023 | 16 | 0.050 |
Why?
| | Risk Factors | 3 | 2013 | 10779 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2005 | 405 | 0.050 |
Why?
| | Sex Factors | 2 | 2019 | 2112 | 0.050 |
Why?
| | Eligibility Determination | 1 | 2022 | 68 | 0.050 |
Why?
| | Telephone | 1 | 2023 | 175 | 0.050 |
Why?
| | Rilpivirine | 1 | 2022 | 10 | 0.050 |
Why?
| | Colorado | 1 | 2012 | 4564 | 0.040 |
Why?
| | Temperature | 2 | 2016 | 679 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2025 | 2029 | 0.040 |
Why?
| | Interviews as Topic | 1 | 2024 | 901 | 0.040 |
Why?
| | Social Support | 1 | 2024 | 652 | 0.040 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2024 | 428 | 0.040 |
Why?
| | Point-of-Care Systems | 1 | 2022 | 187 | 0.040 |
Why?
| | Anti-Bacterial Agents | 1 | 2010 | 1907 | 0.040 |
Why?
| | Drug Combinations | 1 | 2020 | 390 | 0.040 |
Why?
| | Uridine Monophosphate | 1 | 2018 | 16 | 0.040 |
Why?
| | Chemoprevention | 1 | 2018 | 90 | 0.030 |
Why?
| | Chemistry Techniques, Analytical | 1 | 2018 | 20 | 0.030 |
Why?
| | Metabolic Clearance Rate | 1 | 2018 | 114 | 0.030 |
Why?
| | Ribavirin | 1 | 2018 | 80 | 0.030 |
Why?
| | Hospitals | 1 | 2003 | 730 | 0.030 |
Why?
| | Oxazines | 1 | 2018 | 37 | 0.030 |
Why?
| | Healthy Volunteers | 1 | 2018 | 215 | 0.030 |
Why?
| | Neurocognitive Disorders | 1 | 2017 | 33 | 0.030 |
Why?
| | ROC Curve | 1 | 2019 | 614 | 0.030 |
Why?
| | Hepatitis C, Chronic | 1 | 2019 | 152 | 0.030 |
Why?
| | Neoplasms | 1 | 2013 | 2875 | 0.030 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2023 | 1129 | 0.030 |
Why?
| | Area Under Curve | 1 | 2018 | 330 | 0.030 |
Why?
| | Coinfection | 1 | 2018 | 141 | 0.030 |
Why?
| | Enzymes | 1 | 2017 | 65 | 0.030 |
Why?
| | Reproducibility of Results | 2 | 2016 | 3409 | 0.030 |
Why?
| | Survival Analysis | 1 | 2019 | 1382 | 0.030 |
Why?
| | Creatinine | 1 | 2018 | 506 | 0.030 |
Why?
| | Biological Transport | 1 | 2017 | 417 | 0.030 |
Why?
| | Methanol | 1 | 2016 | 46 | 0.030 |
Why?
| | Spermatozoa | 1 | 2016 | 109 | 0.030 |
Why?
| | Solutions | 1 | 2016 | 166 | 0.030 |
Why?
| | Gelatin | 1 | 2015 | 56 | 0.030 |
Why?
| | Down-Regulation | 1 | 2017 | 627 | 0.030 |
Why?
| | Linear Models | 1 | 2016 | 854 | 0.030 |
Why?
| | Patient Compliance | 1 | 2017 | 588 | 0.020 |
Why?
| | Quality Control | 1 | 2013 | 163 | 0.020 |
Why?
| | Calibration | 1 | 2013 | 151 | 0.020 |
Why?
| | Drug Stability | 1 | 2013 | 164 | 0.020 |
Why?
| | Klebsiella Infections | 1 | 2013 | 26 | 0.020 |
Why?
| | Health Surveys | 1 | 2015 | 518 | 0.020 |
Why?
| | Enterobacteriaceae | 1 | 2013 | 43 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2017 | 2027 | 0.020 |
Why?
| | Lung | 1 | 2006 | 4109 | 0.020 |
Why?
| | Water | 1 | 2016 | 469 | 0.020 |
Why?
| | Computer Simulation | 1 | 2016 | 1025 | 0.020 |
Why?
| | Refugees | 1 | 2013 | 81 | 0.020 |
Why?
| | Kidney Failure, Chronic | 1 | 2017 | 598 | 0.020 |
Why?
| | Hospitalization | 1 | 2022 | 2433 | 0.020 |
Why?
| | Prognosis | 1 | 2019 | 4282 | 0.020 |
Why?
| | Haplotypes | 1 | 2012 | 490 | 0.020 |
Why?
| | Epithelial Cells | 1 | 2016 | 1125 | 0.020 |
Why?
| | Cost-Benefit Analysis | 1 | 2012 | 634 | 0.020 |
Why?
| | Models, Biological | 1 | 2016 | 1821 | 0.020 |
Why?
| | Genotype | 1 | 2012 | 1833 | 0.020 |
Why?
| | Lymphomatoid Granulomatosis | 1 | 2006 | 5 | 0.020 |
Why?
| | Histoplasmosis | 1 | 2006 | 15 | 0.020 |
Why?
| | Sporotrichosis | 1 | 2006 | 6 | 0.010 |
Why?
| | Substance-Related Disorders | 1 | 2013 | 1094 | 0.010 |
Why?
| | Sarcoidosis | 1 | 2006 | 160 | 0.010 |
Why?
| | Radiography | 1 | 2006 | 844 | 0.010 |
Why?
| | Biopsy | 1 | 2006 | 1075 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2006 | 1489 | 0.010 |
Why?
| | Practice Guidelines as Topic | 1 | 2006 | 1560 | 0.010 |
Why?
|
|
Castillo-Mancilla's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|